雄激素受體、Stathmin與三陰性乳腺癌臨床病理因素相關性的初步探討_《中國普外基礎與臨床雜志》

作者：

何宇 ^1,2 , 羅靜 ¹ ,  周蕾蕾 ¹

1.四川省醫學科學院·四川省人民醫院乳腺外科（四川成都 610072）;;
2.瀘州市人民醫院外二科（四川瀘州 646100）;

關鍵詞：

三陰性乳腺癌雄激素受體 Stathmin 免疫組織化學臨床病理因素

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

目的　探討雄激素受體（AR）和Stathmin在三陰性乳腺癌患者中的表達情況并分析此與臨床病理因素的相關性。
方法　回顧性收集2005～2009年期間在四川省人民醫院乳腺外科確診為三陰性乳腺癌并符合納入條件患者共83例。使用免疫組織化學EnVision二步法檢測AR和Stathmin蛋白在三陰性乳腺癌中的表達情況。用Spearman檢驗分析AR和Stathmin表達與患者年齡、腫瘤大小、淋巴結狀態及病理分級的相關性。
結果　AR和Stathmin在三陰性乳腺癌組織中表達陽性率分別為37.3% （31/83）和98.8% （82/83）。AR的表達與年齡呈正相關
（rs=0.302，P=0.006），與腫瘤病理分級也呈正相關（rs=0.225，P=0.041），而與腫瘤大小和淋巴結狀態無關（P＞0.05）。
Stathmin的表達與患者年齡、腫瘤大小、淋巴結狀態及病理分級均無關（P＞0.05）。
結論　AR表達與乳腺癌患者的年齡及腫瘤分級有關，而Stathmin與生物學行為無關，其作為三陰性乳腺癌預后判斷指標還需要進一步研究。

引用本文： 何宇,羅靜,周蕾蕾. 雄激素受體、Stathmin與三陰性乳腺癌臨床病理因素相關性的初步探討. 中國普外基礎與臨床雜志, 2013, 20(8): 846-850. doi: 復制

1.	Gluz O， Liedtke C， Gottschalk N， et al. Triple-negative breast cancer-current status and future directions[J]. Ann Oncol， 2009， 20(12)：1913-1927.
2.	Medioni J， Huchon C， Le Frere-Belda MA， et al. Neoadjuvant dose-dense gemcitabine plus docetaxel and vinorelbine plus epiru-bicin for operable breast cancer：improved prognosis in triple-negative tumors[J]. Drugs RD， 2011， 11(2)：147-157.
3.	Liedtke C， Mazouni C， Hess KR， et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer[J]. J Clin Oncol， 2008， 26(8)：1275-1281.
4.	Hanley K， Wang J， Bourne P， et al. Lack of expression of andr-ogen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast[J]. Hum Pathol， 2008， 39(3)：386-392.
5.	Pristauz G， Petru E， Stacher E， et al. Androgen receptor expression in breast cancer patients tested for BRCA1 and BRCA2 muta-tions[J]. Histopathology， 2010， 57(6)：877-884.
6.	Tang D， Xu S， Zhang Q， et al. The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer[J]. Med Oncol， 2012， 29(2)：526-533.
7.	Doane AS， Danso M， Lal P， et al. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen[J]. Oncogene， 2006， 25(28)：3994-4008.
8.	Agoff SN， Swanson PE， Linden H， et al. Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical， clinical， and prognostic associations[J]. Am J Clin Pathol， 2003， 120(5)：725-731.
9.	Brattsand G. Correlation of oncoprotein 18/stathmin expression in human breast cancer with established prognostic factors[J]. Br J Cancer， 2000， 83(3)：311-318.
10.	Baquero MT， Hanna JA， Neumeister V， et al. Stathmin expression and its relationship to microtubule-associated protein tau and outcome in breast cancer[J]. Cancer， 2012， 118(19)：4660-4669.
11.	Rakha EA， Aleskandarany M， El-Sayed ME， et al. The prognosticsignificance of inflammation and medullary histological type ininvasive carcinoma of the breast[J]. Eur J Cancer， 2009， 45(10)：.
12.	Cao AY， He M， Liu ZB， et al. Outcome of pure mucinous breast carcinoma compared to infiltrating ductal carcinoma：a population-based study from China[J]. Ann Surg Oncol， 2012， 19(9)：3019-3027.
13.	Chen WY， Chen CS， Chen HC， et al. Mucinous cystadenocarcinoma of the breast coexisting with infiltrating ductal carcinoma[J]. Pathol Int， 2004， 54(10)：781-786.
14.	Shah C， Wilkinson JB， Shaitelman S， et al. Clinical outcomes using accelerated partial breast irradiation in patients with invasive lobular carcinoma[J]. Int J Radiat Oncol Biol Phys， 2011， 81(4)：.
15.	Fernández B， Paish EC， Green AR， et al. Lymph-node metastasesin invasive lobular carcinoma are different from those in ductal carcinoma of the breast[J]. J Clin Pathol， 2011， 64(11)：995-1000.
16.	Lerma E， Peiro G， Ramón T， et al. Immunohistochemical hetero-geneity of breast carcinomas negative for estrogen receptors，progesterone receptors and Her2/neu (basal-like breast carcinomas)[J]. Mod Pathol， 2007， 20(11)：1200-1207.
17.	Millikan RC， Newman B， Tse CK， et al. Epidemiology of basal-like breast cancer[J]. Breast Cancer Res Treat， 2008， 109(1)：123-139.
18.	Dent R， Trudeau M， Pritchard KI， et al. Triple-negative breast cancer：clinical features and patterns of recurrence[J]. Clin Cancer Res， 2007， 13(15 Pt 1)：4429-4434.
19.	Cimino-Mathews A， Hicks JL， Illei PB， et al. Androgen receptorexpression is usually maintained in initial surgically resected breast cancer metastases but is often lost in end-stage metastases found at autopsy[J]. Hum Pathol， 2012， 43(7)：1003-1011.
20.	Park S， Koo J， Park HS， et al. Expression of androgen receptorsin primary breast cancer[J]. Annals of oncology ：official journal of the European Society for Medical Oncology / ESMO， 2010， 21(3)：488-492.
21.	Niemeier LA， Dabbs DJ， Beriwal S， et al. Androgen receptor in breast cancer：expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation[J]. Mod Pathol， 2010， 23(2)：205-212.
22.	Qi JP， Yang YL， Zhu H， et al. Expression of the androgen receptorand its correlation with molecular subtypes in 980 Chinese breast cancer patients[J]. Breast Cancer (Auckl)， 2012， 6：1-8.
23.	Gonzalez-Angulo AM， Stemke-Hale K， Palla SL， et al. Androgenreceptor levels and association with PIK3CA mutations and prognosis in breast cancer[J]. Clin Cancer Res， 2009， 15(7)：2472-2478.
24.	Loibl S， Müller BM， von Minckwitz G， et al. Androgen receptorexpression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy[J]. Breast Cancer Res Treat， 2011， 130(2)：477-487.
25.	Holmfeldt P， Sellin ME， Gullberg M. Predominant regulators of tubulin monomer-polymer partitioning and their implication for cell polarization[J]. Life Sci， 2009， 66(20)：3263-3276.
26.	Singer S， Ehemann V， Brauckhoff A， et al. Protumorigenic overexpression of stathmin/Op18 by gain-of-function mutation in p53 in human hepatocarcinogenesis[J]. Hepatology， 2007， 46(3)：759-768.
27.	Alli E， Bash-Babula J， Yang JM， et al. Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer[J]. Cancer Res， 2002， 62(23)：6864-6869.
28.	Alli E， Yang JM， Ford JM， et al. Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cells[J]. Mol Pharmacol， 2007， 71(5)：1233-1240.
29.	Kavallaris M. Microtubules and resistance to tubulin-binding agents[J]. Nat Rev Cancer， 2010， 10(3)：194-204.
30.	-551.
31.	-1787.

1. Gluz O， Liedtke C， Gottschalk N， et al. Triple-negative breast cancer-current status and future directions[J]. Ann Oncol， 2009， 20(12)：1913-1927.
2. Medioni J， Huchon C， Le Frere-Belda MA， et al. Neoadjuvant dose-dense gemcitabine plus docetaxel and vinorelbine plus epiru-bicin for operable breast cancer：improved prognosis in triple-negative tumors[J]. Drugs RD， 2011， 11(2)：147-157.
3. Liedtke C， Mazouni C， Hess KR， et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer[J]. J Clin Oncol， 2008， 26(8)：1275-1281.
4. Hanley K， Wang J， Bourne P， et al. Lack of expression of andr-ogen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast[J]. Hum Pathol， 2008， 39(3)：386-392.
5. Pristauz G， Petru E， Stacher E， et al. Androgen receptor expression in breast cancer patients tested for BRCA1 and BRCA2 muta-tions[J]. Histopathology， 2010， 57(6)：877-884.
6. Tang D， Xu S， Zhang Q， et al. The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer[J]. Med Oncol， 2012， 29(2)：526-533.
7. Doane AS， Danso M， Lal P， et al. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen[J]. Oncogene， 2006， 25(28)：3994-4008.
8. Agoff SN， Swanson PE， Linden H， et al. Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical， clinical， and prognostic associations[J]. Am J Clin Pathol， 2003， 120(5)：725-731.
9. Brattsand G. Correlation of oncoprotein 18/stathmin expression in human breast cancer with established prognostic factors[J]. Br J Cancer， 2000， 83(3)：311-318.
10. Baquero MT， Hanna JA， Neumeister V， et al. Stathmin expression and its relationship to microtubule-associated protein tau and outcome in breast cancer[J]. Cancer， 2012， 118(19)：4660-4669.
11. Rakha EA， Aleskandarany M， El-Sayed ME， et al. The prognosticsignificance of inflammation and medullary histological type ininvasive carcinoma of the breast[J]. Eur J Cancer， 2009， 45(10)：.
12. Cao AY， He M， Liu ZB， et al. Outcome of pure mucinous breast carcinoma compared to infiltrating ductal carcinoma：a population-based study from China[J]. Ann Surg Oncol， 2012， 19(9)：3019-3027.
13. Chen WY， Chen CS， Chen HC， et al. Mucinous cystadenocarcinoma of the breast coexisting with infiltrating ductal carcinoma[J]. Pathol Int， 2004， 54(10)：781-786.
14. Shah C， Wilkinson JB， Shaitelman S， et al. Clinical outcomes using accelerated partial breast irradiation in patients with invasive lobular carcinoma[J]. Int J Radiat Oncol Biol Phys， 2011， 81(4)：.
15. Fernández B， Paish EC， Green AR， et al. Lymph-node metastasesin invasive lobular carcinoma are different from those in ductal carcinoma of the breast[J]. J Clin Pathol， 2011， 64(11)：995-1000.
16. Lerma E， Peiro G， Ramón T， et al. Immunohistochemical hetero-geneity of breast carcinomas negative for estrogen receptors，progesterone receptors and Her2/neu (basal-like breast carcinomas)[J]. Mod Pathol， 2007， 20(11)：1200-1207.
17. Millikan RC， Newman B， Tse CK， et al. Epidemiology of basal-like breast cancer[J]. Breast Cancer Res Treat， 2008， 109(1)：123-139.
18. Dent R， Trudeau M， Pritchard KI， et al. Triple-negative breast cancer：clinical features and patterns of recurrence[J]. Clin Cancer Res， 2007， 13(15 Pt 1)：4429-4434.
19. Cimino-Mathews A， Hicks JL， Illei PB， et al. Androgen receptorexpression is usually maintained in initial surgically resected breast cancer metastases but is often lost in end-stage metastases found at autopsy[J]. Hum Pathol， 2012， 43(7)：1003-1011.
20. Park S， Koo J， Park HS， et al. Expression of androgen receptorsin primary breast cancer[J]. Annals of oncology ：official journal of the European Society for Medical Oncology / ESMO， 2010， 21(3)：488-492.
21. Niemeier LA， Dabbs DJ， Beriwal S， et al. Androgen receptor in breast cancer：expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation[J]. Mod Pathol， 2010， 23(2)：205-212.
22. Qi JP， Yang YL， Zhu H， et al. Expression of the androgen receptorand its correlation with molecular subtypes in 980 Chinese breast cancer patients[J]. Breast Cancer (Auckl)， 2012， 6：1-8.
23. Gonzalez-Angulo AM， Stemke-Hale K， Palla SL， et al. Androgenreceptor levels and association with PIK3CA mutations and prognosis in breast cancer[J]. Clin Cancer Res， 2009， 15(7)：2472-2478.
24. Loibl S， Müller BM， von Minckwitz G， et al. Androgen receptorexpression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy[J]. Breast Cancer Res Treat， 2011， 130(2)：477-487.
25. Holmfeldt P， Sellin ME， Gullberg M. Predominant regulators of tubulin monomer-polymer partitioning and their implication for cell polarization[J]. Life Sci， 2009， 66(20)：3263-3276.
26. Singer S， Ehemann V， Brauckhoff A， et al. Protumorigenic overexpression of stathmin/Op18 by gain-of-function mutation in p53 in human hepatocarcinogenesis[J]. Hepatology， 2007， 46(3)：759-768.
27. Alli E， Bash-Babula J， Yang JM， et al. Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer[J]. Cancer Res， 2002， 62(23)：6864-6869.
28. Alli E， Yang JM， Ford JM， et al. Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cells[J]. Mol Pharmacol， 2007， 71(5)：1233-1240.
29. Kavallaris M. Microtubules and resistance to tubulin-binding agents[J]. Nat Rev Cancer， 2010， 10(3)：194-204.
30. -551.
31. -1787.

《中國普外基礎與臨床雜志》

雄激素受體、Stathmin與三陰性乳腺癌臨床病理因素相關性的初步探討

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

《中國普外基礎與臨床雜志》

雄激素受體、Stathmin與三陰性乳腺癌臨床病理因素相關性的初步探討

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料